Two episodes of systemic capillary leak syndrome in an 8-year-old boy, following influenza A virus infection.

Pediatr Infect Dis J

From the *University Medical Centre Ljubljana, Zaloska,; †Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva; ‡Department of Allergology, Rheumatology and Clinical Immunology; §Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre, Bohoriceva; ¶Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloska; ‖Department of Pediatric Surgery and Intensive Therapy, University Medical Centre Ljubljana, Bohoriceva; and **Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, Slovenia.

Published: February 2014

Systemic capillary leak syndrome is a rare condition, characterized by hypotension, edema, hemoconcentration and hypoalbuminemia. We describe 2 episodes of systemic capillary leak syndrome, following influenza A virus infection, occurring during 2 subsequent influenza seasons, in an 8-year-old boy.

Download full-text PDF

Source
http://dx.doi.org/10.1097/INF.0000000000000029DOI Listing

Publication Analysis

Top Keywords

systemic capillary
12
capillary leak
12
leak syndrome
12
episodes systemic
8
8-year-old boy
8
influenza virus
8
virus infection
8
syndrome 8-year-old
4
boy influenza
4
infection systemic
4

Similar Publications

IL-1β primed mesenchymal stromal cells moderate hemorrhagic shock-induced vascular permeability.

J Transl Med

December 2024

Institut de Recherche Biomédicale Des Armées (IRBA), 1, Rue du Lieutenant Raoul Batany, 92141, Clamart, France.

Background: Hemorrhagic shock (HS) corresponds to absolute hypovolemia creating an imbalance between oxygen supply and consumption. This causes an impaired hemostasis, a systemic inflammatory response, and microvascular permeability which can lead to multiple organ failure (MOF). There is no specific treatment for the endothelial dysfunction that plays a major role in the evolution towards MOF.

View Article and Find Full Text PDF

Circular Shunt: A Loop Not to Be Ignored.

J Cardiothorac Vasc Anesth

December 2024

Department of Cardiothoracic Surgery, National Heart Center, Royal Hospital, Muscat, Oman.

A circular shunt, initially described by Shone et al. in 1962, refers to abnormal blood recirculation through complete intracardiac or intra- and extracardiac communications, bypassing the capillary beds. This pathophysiological condition is most commonly associated with complex congenital heart defects, such as Ebstein's malformation, pulmonary atresia, Gerbode defect, and so on.

View Article and Find Full Text PDF

Transient receptor potential vanilloid 4 gene-deficiency attenuates the inhibitory effect of 5,6-dihydroxy-8Z,11Z,14Z,17Z-eicosatetraenoic acid on vascular permeability in mice.

J Pharmacol Sci

January 2025

Department of Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan; Department of Veterinary Pharmacology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan; Food and Animal Systemics, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan. Electronic address:

We investigated whether an anti-inflammatory lipid metabolite named 5,6-DiHETE reduces vascular permeability by inhibiting TRPV4 channels in vivo. In wild-type (WT) mice, histamine-induced dye extravasation was reduced by pre-administration of 5,6-DiHETE. In TRPV4-deficient mice, extravasation and histamine-induced edema were already reduced, and 5,6-DiHETE had no additional effect.

View Article and Find Full Text PDF

Systemic capillary leak syndrome (SCLS) is a rare life-threatening disorder due to profound vascular leak. The trigger and the cause of the disease are currently unknown and there is no specific treatment. Here, we identified a rare heterozygous splice-site variant in the TLN1 gene in a familial SCLS case, suggestive of autosomal dominant inheritance with incomplete penetrance.

View Article and Find Full Text PDF

Purpose: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL).

Patients And Methods: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!